Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism.
Secretin has been proposed as a treatment alternative for autistic spectrum disorders, but empirical support is lacking. A double-blind placebo-controlled study examined the effect of a single dose of synthetic human secretin on aberrant behavior. Parent and teacher data from the Aberrant Behavior Checklist for eight male children were analyzed for reliable change in a clinical replication series. By parent and teacher report, the majority of change occurred either on the placebo trial or reflected deterioration subsequent to secretin infusion. Repeated-measures multivariate analysis of variance results were similar. Results are consistent with other studies, suggesting that secretin may not be an effective treatment option.
Carey
Tracy
T
Department of Pediatrics, Medical College of Ohio, Toledo 43608, USA. TCarey@mc.edu
Ratliff-Schaub
Karen
K
Funk
Jeanne
J
Weinle
Chris
C
Myers
Melissa
M
Jenks
Jennifer
J
D001321:Autistic Disorder / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002653:Child Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy*; D002675:Child, Preschool; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006728:Hormones / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010552:Personality Assessment; D012633:Secretin / Q000009:adverse effects / Q000627:therapeutic use*
D006728:Hormones; D012633:Secretin